[ad_1]
NEW YORK, April 16, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.
MindMed is developing 18-MC as a potential treatment for ...
[ad_1]
Fighting Opioid Dependency with Plant-Based Medicine
This Universal Ibogaine profile is part of a paid investor education campaign.*
Universal Ibogaine is a Canadian company working to develop compounds to combat the opioid epidemic through plant-based medicine. The company aims to operate and franchise clinics around the world, offering ibogaine as a treatment for opioid-based ...
[ad_1]
Our Ibogaine natural detox therapy is opiods free and keep you out of the dangers of Suboxine,Suboxone into your blood stream.Stop suffering in …
[ad_2]
Source link
[ad_1]
… experiments with psilocybin mushrooms and the hallucinogenic plant iboga to treat her seemingly intractable dependence on heroin, methadone or …
[ad_2]
Source link
[ad_1]
No one wakes up one day and decides to become opioid dependent. You might have been warned against the risks – aware that there’s a chance of developing a tolerance or dependence on the drugs. At the start they block the pain and release that feel-good ...